Cantor Fitzgerald analyst Charles Duncan raised the firm’s price target on Catalyst Pharmaceuticals to $27 from $25 and keeps an Overweight rating on the shares. Having reported its strongest-ever revenue quarterly performance, Cantor believes that the company has demonstrated good commercial execution, highlighted by 22% y/y growth in FIRDAPSE sales and a guidance raise for FY23 total sales to $380M-$390M from $375-385M, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CPRX:
- Catalyst Pharmaceuticals sees FY23 revenue $380M-$390M, consensus $380.21M
- Catalyst Pharmaceuticals reports Q2 EPS 53c, consensus 42c
- Catalyst Pharmaceuticals Reports Strong Second Quarter 2023 Financial Results and Provides Corporate Update
- CPRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Catalyst Pharmaceuticals CEO McEnany announces intention to retire